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Despite overall progress in global TB control, the rising burden ofmultidrug-resistant TB (MDR-TB) threatens to under-
mine efforts to end theworldwide epidemic. Of the 27 countries classified as high burden for MDR-TB, 17 are in ‘low’
or ‘low–middle’ income countries. Shorter, all oral and less toxic multidrug combinations are required to improve
treatment outcomes in these settings. Suitability for safe co-administration with HIV drugs is also desirable. A
range of strategies and several new drugs (including bedaquiline, delamanid and linezolid) are currently undergoing
advanced clinical evaluations to define their roles in achieving these aims. However, several clinical questions and
logistical challenges need to be overcome before these new MDR-TB treatments fulfil their potential.
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Introduction
Theworldwide incidence of new TB cases has been in decline since
2005, and in September 2015WHO announced that the TB target
of Millennium Development Goal 6—halting and reversing spread
of the disease—had been achieved.1 New targets include ending
the TB epidemic by 2030.2 However, sustained progress is threa-
tened by the spectre of antimicrobial resistance to first-line ther-
apy. Multidrug-resistant (MDR) TB is caused by Mycobacterium
tuberculosis organisms that are resistant to rifampicin and isoni-
azid, and the estimated number of new MDR-TB cases rose from
250 000 in 2009 to 480 000 in 2013.3 Extensively drug-resistant
TB (XDR-TB) is defined as MDR-TBwith additional resistance to any
fluoroquinolone and any of the three second-line injectable
agents (amikacin, capreomycin and kanamycin); 9% of MDR-TB
cases fulfil these criteria, and XDR-TB has been identified in over
100 countries.3
The second-line drugs (SLDs) required to treat MDR-TB and
XDR-TB are expensive and difficult to obtain. Of the 27 countries
classified as ‘high burden’ for MDR-TB, 17 are in ‘low’ or ‘lower–mid-
dle’ income countries (see Figure 1), where these challenges are
most daunting. Even in ‘high–middle’ or ‘high’ income countries,
MDR-TB patients tend to be clustered amongst hard-to-reach
groups. From 2012 to 2013 the gap between numbers of patients
diagnosed and initiated on therapy for MDR-TB increased in many
places. In 10 high-burden countries, ,60% of diagnosed cases
received treatment in 2013; the lowest rates were described in
Tajikistan (30%), Myanmar (34%) and South Africa (41%).3
After treatment initiation, MDR-TB therapy currently takes at
least 20months to complete,4,5with close monitoring for adverse
drug reactions. This is a formidable task. Although five high-
burden countries (Ethiopia, Kazakhstan, Myanmar, Pakistan and
Vietnam) reported favourable outcome rates of≥70%, worldwide
treatment success of patients diagnosed with MDR-TB in 2011
was only 48%. For 1269 XDR-TB patients, successful treatment
completion was only observed in 22% and 35% of patients
died.3 In a cohort of 107 XDR-TB patients treated in South Africa
mortality at 70 months was 78%.6
Better MDR-TB treatments and expanded access to therapy are
urgently required. In recent years, several innovative approaches
and novel drugs have been clinically assessed. This review
describes these advances, highlights areas of ongoing uncertainty
and discusses practical aspects of improving access to therapy in
the countries of greatest need.
Multidrug-resistant TB treatment and drug
susceptibility testing
More effective treatment will require earlier diagnosis; in 2013,
55% of reported TB patients estimated to have MDR-TB were
not identified,3 partly because of limited laboratory facilities for
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TB culture and drug susceptibility testing (DST). Ongoing roll-out
of molecular tests (e.g. Xpert MTB/RIF and line probe assays
[LPAs]) will facilitate faster detection of rifampicin and isoniazid
resistance, and WHO guidance states that ‘standardised’
second-line antibiotic combinations may then be based on epi-
demiological resistance data.4 While this is feasible and cost-
effective in the absence of additional SLD resistance,7,8 recent
data warn of a growing need for more comprehensive DST in
order to provide ‘individualised’ therapy for complex patients.9
A recent observational study revealed that 24.1% of MDR-TB
patients across nine countries in Asia, Europe and Africa had
pre-XDR-TB (defined as baseline resistance to fluoroquinolones
or second-line injectable drugs but not both).10 Fluoroquinolone
resistance is associated with poor prognosis11–13 and acquisi-
tion of additional resistance during therapy,14 so SLD resistance
has implications for regimen selection. Although a detailed dis-
cussion of DST is beyond the scope of this review, these data
emphasise that novel therapeutic strategies for resource-poor
countries will be most successful if embedded within a broader
package of TB control tools.
Current guidelines and management
challenges
Current WHO guidelines group anti-TB drugs into five classes and
provide principles for the design of MDR-TB treatment regimens
(Figure 2).4,15 At least five drugs (including an injectable agent)
should be given for an ‘intensive phase’ of up to 8 months.
Thereafter, a ‘continuation phase’ of least four oral drugs should
be continued until a total minimum duration of 20 months
(Figure 3). Prolonged therapy maximises the likelihood of long
term cure without relapse,16 but presents a range of practical
challenges.
Firstly, injections generally require prolonged hospitalisation or
daily clinic attendance, generating high healthcare and societal
costs. The aminoglycoside drugs (amikacin and kanamycin)
used for parenteral therapy cause nephro- and ototoxicity; a
recent systemic review reported hearing loss in 18–62% of
patients.17 Although some interventions (e.g., co-administration
prophylactic N-acetyl cysteine18) have been proposed to amelior-
ate this and capreomycin injections may be less ototoxic,19
all-oral, safer treatments are clearly desirable.
Figure 1. High-burdenmultidrug-resistant TB (MDR-TB) countries by income status. According to theWorld Bank, low-income economies are defined as
those with an annual Gross National Income (GNI) per capita of ,US$1045, low–middle income economics have a GNI per capita of US$1045–4125,
high-middle income economies have a GNI per capita of US$4125–12 746 and high-income economies have a GNI per capita of .US$12 746.
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Figure 2. WHO recommended groupings ofmultidrug-resistant TB (MDR-TB) drugs. aThere are high rates of streptomycin resistance in MDR-TB strains; it
is not considered a second line anti-TB injectable agent. bGatifloxacin may have side-effects including dysglycaemia. It has been removed from the
market in several countries. Early generation fluoroquinolones do not high adequate activity against MDR-TB. cTerizidone may also be listed as Group
4 anti-TB drug. It has limited programmatic and efficacy data compared to the others. dOther Group 5 drugs, with variable in vitro and animal data to
support use include amoxicillin/calvulanate, imipenem/cilastatin, meropenem, thioacetazone and clarithromycin.
Figure 3. CurrentWHO recommended design ofmultidrug-resistant TB regimens. aThereare conditions inwhichadditional drugs areused. These conditions
are applicable when the effectiveness for one ormore drugs is unlikely or questionable. One important example of this would be treatment of extensively drug-
resistant TB (XDR-TB). If an appropriate regimen cannot be constructed using Group 1–4 drugs, Group 5 drugs may be used. bSome examples of high
cross-resistance include: there is high cross-resistance between isoniazid and prothionamide/ethionamide if the InhA mutation is present in the
Mycobacterium tuberculosis isolate, amikacin and kanamycin have very high cross-resistance, fluroquinolones have variable cross-resistance.
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Secondly, TB control programmes that successfully support
patients through the ‘intensive phase’ of therapy often encounter
high loss-to-follow up during the ‘continuation phase’. A tertiary
care facility in Ukraine described that, in a cohort of 484 MDR-TB
patients from 2006–2011, 67% successfully completed injectable
treatment but only 22% had favourable outcomes at 20 months.
No final outcome could be recorded for 51%, indicating poor reten-
tion in care.20 Factors implicated in poor treatment adherence
amongst MDR-TB patients in India include perceived lack of
provider-initiated support and financial constraints.21 Some of
these may be remediable but shorter total treatment is required.
Finally, especially in Africa, drug-resistant TB is a particular risk
to individuals with HIV with high transmission of infection and
high mortality.22 Compared to treatment of drug-susceptible TB
with rifampicin, there are few drug–drug interactions (DDIs)
between second-line anti-TB drugs and antiretroviral therapy
(ART). However, toxicities may overlap and information on DDIs
of new anti-TB drugs is incomplete. The complexity of managing
HIV-TB co-infection must remain a key consideration as novel
treatments are introduced.
Overall, current global experience confirms that desirable char-
acteristics of new MDR-TB treatments include provision of all-oral,
less toxic, shorter duration regimens without DDIs, particularly in
relation to ART.23
Shortening therapy with existing drugs
One approach to shortening therapy is to use a different com-
bination of agents from existing anti-TB drug groups. From
1997–2007 sequentially adapted treatment regimens were
administered to serial MDR-TB cohorts in Bangladesh until it
was demonstrated that 4 months of seven drugs (kanamycin,
clofazimine, gatifloxacin, ethambutol, high-dose isoniazid, pyr-
azinamide and prothionamide) followed by 5 months of four
drugs (gatifloxacin, ethambutol, pyrazinamide and clofazimine)
achieved a relapse-free cure rate of 88%.24 An additional report
from the same setting was similarly impressive.25 A closely
related 12-month regimen achieved 89% treatment success in
Cameroon where HIV sero-prevalence amongst TB patients is
higher (20% vs,0.5% in Bangladesh).26 These results are sum-
marised in Table 1.
The authors of the Bangladesh regimen attributed successful
abbreviation of therapy to the introduction of clofazimine and
a high-dose fourth generation fluoroquinolone (gatifloxacin,
400–800 mg/day according to weight). Few other studies have
confirmed the tolerability of high-dose fluoroquinolones27 and
the investigators in Cameroon preferred a standard dose of
400 mg gatifloxacin for all patients. In both studies, follow-up
took place under routine conditions; the Bangladesh programme
stated that they could deliver their treatment very cheaply, for
E200 (US$218) per patient.24
Several issues require consideration before 9–12 month
MDR-TB treatment regimens are approved for general use in
resource-poor settings. Evidence for their efficacy comes exclu-
sively from observational studies and is sparse when compared
to the standard of care approach.16 Key components of the
shorter regimens (e.g., clofazimine and fluoroquinolones) can pro-
long the corrected QT interval (QTc) on electrocardiograms
(ECGs).28 The extent to which this increases the risk of life-
threatening arrhythmias is unknown and requires active phar-
macovigilance. A randomised clinical trial is ongoing to directly
compare a variant of the Bangladesh regimen (with moxifloxacin
substituted for gatifloxacin) against current WHO recommenda-
tions and should answer some of these questions in 2017 (the
standardised treatment regimen of anti-tuberculosis drugs for
patients with multiple drug-resistant tuberculosis [STREAM] trial,
www.isrctn.com: ISRCTN78372190).29 Until then, countries are
only advised to introduce short MDR-TB regimens if the project
Table 1. Recent evaluations of short (9 to 12-month) multidrug-resistant TB regimens
Site and date
of report
Regimen No.
patients
Time to 95%
treatment
completion
Treatment success,
n (%)
Non-success, n (%)
Intensive Continuation Cure Completed Failure Death Default Relapsec
Bangladesh,
201024
4Km-Cfz-Gh--E-Hh-Z-Pto
a 5Gh-E-Z-Cfz 206 365 days 170 (82.5) 11 (5.3) 1 (0.5) 11 (5.3) 12 (5.8) 1 (0.5)
Bangladesh,
201425
4Km-Cfz-Gh--E-Hh-Z-Pto
a 5Gh-E-Z-Cfz 515b 363 days 418 (81.2) 17 (3.3) 7 (1.4) 29 (5.6) 40 (7.8) 4 (0.8)
Cameroon,
201526
4Km-Cfz-G-E-H-Z-Ptoa 8G-Cfz-Z-E-Pto 150 409 days 132 (88.0) 2 (1.3) 1 (0.7) 10 (6.7) 5 (3.3) 0
Numbers in front of drug combinations indicate planned months of therapy.
Cfz: clofazimine (50–100 mg); E: ethambutol (800–1200 mg); G: gatifloxacin (400 mg to all patients); Gh: gatifloxacin high dose (400–800 mg); H:
isoniazid (300 mg to all patients); Hh: isoniazid high dose (300–600 mg); Km: kanamycin (500–1000 mg); Pto: prothionamide (500–1000 mg); Z:
pyrazinamide (800–2000mg). Dose ranges indicate adjustment by weight.
a Intensive phase therapy extended until sputum smear conversion if not smear negative at 4 months.
b The second Bangladesh study represents a cumulative total of patients on the ‘Bangladesh’ regimen, so includes longer-term follow-up data on
patients from the first study in addition to new data.
c Completion of 24 month follow-up to detect relapse amongst patients with treatment success was variable between these studies; 54% and
93%, respectively, in the Bangladesh studies and 75% in Cameroon.
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is prospectively approved by a national ethics review committee;
treatment is administered under operational research conditions;
and the project is independently monitored by a board reporting
to WHO.4
It is also noteworthy that short treatment regimens have not
been evaluated in XDR-TB and high-level fluoroquinolone
resistance was a risk factor for unsuccessful outcomes in
Bangladesh.25 These findings further advocate for expanded
access to full DST and suggest that ≤12-month regimens should
not currently be considered for XDR-TB patients.
An alternative approach to improvedMDR- and XDR-TB therapy
is to bolster regimens with newmedications, some of which open
up the possibility of all-oral therapy and remove the problems
associated with injectable drugs. Examples of this approach
(e.g., STREAM-II, NEXT, NixTB, PRACTECAL and end TB trials) are
summarised in Table 2 and discussed in relevant later sections
of this review.
Bedaquiline
The diarylquinoline, bedaquiline, is the first new anti-TB drug for
over 40 years.30 Alongside delamanid and linezolid (discussed
below), it is currently listed in WHO Group 515 (see Figure 2).
These classifications may change as efficacy and safety data
emerge.
Bedaquiline is orally administered and acts via a novel mech-
anism that selectively inhibits mycobacterial adenosine tri-
phosphate synthase.30,31 Early clinical studies indicated high
bactericidal activity against drug-susceptible and resistant dis-
ease; the most compelling evidence was from a multicentre
phase II trial (TMC207-C208) in which aWHO-approved optimised
background regimen (OBR) for pulmonaryMDR-TBwas supplemen-
ted, for the first 24 weeks, with either bedaquiline or placebo.
Patients on bedaquiline achieved higher rates of sputum culture
conversion at 24 weeks (79% vs 58%, p¼0.008) and cure at 120
weeks (58% vs 32%, p¼0.003).32–34 Accelerated regulatory
approval followed in a number of countries to permit use of beda-
quiline during the ‘intensive phase’ of prolonged regimens for
pre-XDR and XDR-TB. Encouraging initial experiences have been
reported35,36 but it is not yet known whether the drug also has
treatment-shortening potential. To investigate this possibility,
6- and 9-month bedaquiline-containing arms have been added
to the STREAM trial (STREAM Stage 2, www.clinicaltrials.gov:
NCT02409290). The Nix-TB (www.clinicaltrials.gov: NCT023337
99) and NEXT (www.clinicaltrials.gov: NCT02454205) trials pro-
pose a similar approach, but feature additional new anti-TB
agents (see Table 2). These trials will not report until at least
2019. The phase II/III PRACTECALand endTB trials will incorporate
bedaquiline, in addition to nitroimidazoles in some treat-
ment arms.
There are safety concerns with bedaquiline. During TMC207-
C208,more deathswere observed amongst patients who received
the study drug than placebo (10 vs 2, p¼0.03).Whilst these excess
deaths were not felt to bemedication-related, bedaquiline causes
QTc prolongation, is extensively distributed in peripheral tissues
and has a terminal half-life of 5.5months. Anxiety about accumu-
lative toxicity will persist until phase III clinical trial data are avail-
able. Until these questions are resolved, WHO interim guidance
restricts bedaquiline use to pre-XDR or XDR-TB patients
(necessitating second-line DST) in national TB programmes cap-
able of clinical safety monitoring including ECGs.4,37
Further questions complicate the provision of bedaquiline to
vulnerable patient groups; there are no current trial data for chil-
dren, extra-pulmonary TB, or pregnant and breast-feeding
women. HIV-infected persons are under-represented in existing
studies and there is a lack of information on DDIs with ART.
Bedaquiline is metabolised for excretion by hepatic cytochrome
P450 (CYP) enzymes; co-administration with CYP-inducing ART
drugs (e.g., efavirenz) may reduce effective concentrations,
while CYP-inhibitors (e.g., ritonavir) may precipitate accumulation.
The clinical consequences of these interactions are unknown.
In low-resource settings, issues of cost are also pressing;
in the UK, a 24-week course of bedaquiline costs £18 700
(US$ 28 400),38 which is unaffordable for many high-burden
countries. Janssen, the manufacturer, has developed a differen-
tial pricing strategy, and has donated over 30 000 bedaquiline
courses to be distributed free of charge to low-resource coun-
tries39 but there remains a need for an equitable and sustainable
long-term strategy.
Overall, while bedaquiline represents a potentially exciting
advance in MDR-TB therapy, its role remains to be clearly defined
and expanded access to resource-poor countries faces a series of
logistical challenges.
Nitroimidazoles
Two new drugs of the nitroimidazole class are also undergoing
advanced clinical assessment for the treatment of MDR-TB: dela-
manid and pretomanid. These drugs are structurally related to
metronidazole and inhibit mycolic acid synthesis in the mycobac-
terial cell wall.40 They are both orally administered.
Delamanid is more advanced in clinical evaluation. A Phase IIb
randomised controlled trial in adults with pulmonary MDR-TB,
showed improved rates of sputum culture conversion at 2months
when an OBR was augmented with delamanid as compared to
placebo (45.4% vs 29.6%, p¼0.008).41 An open-label extension
of this trial found that patients who took delamanid for 2–6
months had more favourable outcomes (cured or completed
treatment) (75% vs 55% p,0.001) and lower mortality (1% vs
8%, p,0.001)42 than those who took delamanid for ≤2 months.
A mortality benefit was also seen in XDR-TB (0% vs 25%,
p,0001).43 So far, these promising Phase II data have prompted
accelerated regulatory approval in Europe and Japan. WHO
interim guidance has been issued to inform programmatic
use.44 Phase III trials in adults are planned or underway (see
Table 2). Part 1 of the endTB trial will evaluate a number of
9-month bedaquiline or delamanid-containing regimens using
an adaptive-randomisation study design in which analysis of
accumulative data accelerates trial progression by allowing
decreased randomisation to regimens with poorer outcomes.45
Although there have been no reports of excess mortality in
patients receiving delamanid, there are toxicity concerns.
Delamanid also prolongs the QTc interval on ECG, particularly
via the DM-6705 metabolite. Formation of DM-6705 is regulated
by serum albumin and use of the drug is contraindicated in
patients with hypoalbuminaemia (,2.8 g/dL).
No patients in the published studies on delamanid were from
sub-Saharan Africa and only 1%had HIV. Healthy volunteer studies
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Table 2. Ongoing and planned Phase III trials of bedaquiline, delamanid, pretomanid and linezolid
Study Location(s) Participants Regimens Planned number of
participants
Due to
report
STREAM Stage 2
NCT024092290
Ethiopia
Mongolia
South Africa
Vietnam
MDR-TB OBR
4Km-Cfz-Mfx-E-Hh-Z-Pto5Mfx-E-Z-Cfz
6Bdq-Km-Lfx-Cfz-Z
9Bdq-Lfx-Cfz-Z-Hh-Pto
1155 2021
Nix-TB
NCT02333799
South Africa MDR-TB
XDR-TB
6Bdq-Pa-Lzd
(Single arm study)
200 2021
NEXT
NCT02454205
South Africa MDR-TB OBR
6–9Bdq-Lfx-Lzd-Eto-Z
6–9Bdq-Lfx-Lzd-Eto-H
6–9Bdq-Lfx-Lzd-Eto-Trd
300 2019
NCT01424670 Estonia, Latvia, Lithuania, Moldova, Peru, Philippines, South Africa MDR-TB 6OBR-Dlm
6OBR-Placebo
511 2017
STAND
NCT02342886
Brazil, China, Georgia, Haiti, Kenya, Malaysia, Mozambique, Peru,
Philippines, Russia, South Africa, Tanzania, Thailand, Uganda,
Ukraine, Zambia
DS-TB
MDR-TB
XDR-TB
6Pa-Mfx-Z
2HRZE4RH (control arm in DS-TB only)
1500 2018
PRACTECAL Uzbekistan
Swaziland
MDR-TB
XDR-TB
Bdq-Pa-Lzd-Mfx
Bdq-Pa-Lzd-Cfz
Bdq-Pa-Lzd
OBR
630 2020
endTB (Part 1) Kazakhstan, Kyrgyzstan, Lesotho, Peru, and Georgia MDR-TB Bdq-Lzd-Hh-Mfx-Z
Bdq-Cfz-Lzd-Lfx-Z
Dlm-Lzd-Hh-Mfx-Z
Dlm-Cfz-Lzd-Lfx-Z
Dlm-Cfz-Mfx-Z
OBR (may include Dlm or Bdq)
600 2019
All studies are recruiting adults with pulmonary TB.
Numbers in front of drug regimens indicate planned months of therapy.
Bdq: bedaquiline; Cfz: clofazimine; Dlm: delamanid; DS-TB: drug-sensitive TB; E: ethambutol; Eto: ethionamide; H: isoniazid; Hh: high-dose isoniazid; Km: kanamycin;
Lfx: levofloxacin; Lzd: linezolid; MDR-TB: multidrug-resistant TB; Mfx: moxifloxacin; OBR: optimised background regimen; Pa: pretomanid; Pto: prothionamide; R: rifampicin;
T: terizadone; XDR-TB: extensively drug-resistant TB; Z: pyrazinamide.
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have assessed co-administration with ART and the results are pro-
visionally reassuring; delamanid did not affect exposure to the
anti-HIV medicines tenofovir, lopinavir/ritonavir and efavirenz.
Lopinavir/ritonavir administration increased delamanid and
DM-6705 exposure by 25%.46 The clinical significance of this is
unclear and DDI analysis on HIV-TB patients is needed before con-
fident recommendations on co-prescription can be issued.
Experience of delamanid use in low-resource settings is more
limited than bedaquiline, due to lack of regulatory approval in high-
burden countries and a less developed compassionate-use pro-
gramme.47 The market price is similar to that of bedaquiline,38
and there will be similar obstacles to providing sustainable access.
Otsuka, themanufacturer, has recently announced a targeted drug
donation programme. WHO advice to national TB programmes
wishing to provide delamanid is that MDR-TB patients should be
appropriately consented to receive an experimental drug and a
secure infrastructure for pharmacovigilance should be in place.4,44
There are no published or registered evaluations of bedaquiline
and delamanid being used in the same regimen. Manufacturers of
both drugs andWHO currently recommend against this. Given the
long half-life, patients who have previously received bedaquiline
must wait 6 months before delamanid is considered. As the half-
life of delamanid is much shorter (38 hours) a minimum washout
period of 5 days is advised before replacement with bedaquiline.4
A US National Institutes of Health-sponsored study (ACTG 5343)
to assess DDIs during co-administration of bedaquiline and
delamanid in South Africa will provide more information.
Dependent on the result of this study, part 2 of the endTB trial
may assess the clinical efficacy of regimens containing both
agents, including recruitment of patients with fluoroquinonole
resistant pre-XDR-TB.
The second nitroimidazole compound, pretomanid is not cur-
rently licenced and is not available for compassionate use.
However, Phase II studies in drug-susceptible TB have demon-
strated impressive bactericidal activity from a combination of pre-
tomanid, moxifloxacin and pyrazinamide during the first 2–8
weeks of therapy.48,49As this regimen does not contain rifampicin
or isoniazid, it mayalso be effective inMDR-TB but data supporting
this is currently limited to nine patients.49 The Phase III
Shortening Treatments by Advancing New Drugs (STAND) Trial
(www.clinicaltrials.gov, NCT02342886) will explore this further
at 50 sites worldwide.
A combination of bedaquiline-pretomanid-linezolid has under-
gone Phase IIa evaluation50 and is being considered as rescue ther-
apy for XDR-TB in the open label, single arm Phase III NiX TB trial in
South Africa (see Table 2). The randomised, open-label phase II/III
TB-PRACTECAL trial, which features several pretomanid-containing
regimens andwill begin recruiting in Uzbekistan and Swaziland late
in 2015. As with endTB, this trial will feature an adaptive design in
which less successful arms are discontinued to allow more power-
ful comparison of the most promising regimens. Therefore, while
programmatic access to pretomanid is some way off, experience
of use in resource-poor settings via clinical trials is set to expand
dramatically in the near future.
Linezolid
Another new drug class of particular interest in MDR-TB manage-
ment are the oxazodilines. Linezolid is the most established agent
in this class and achieves broad-spectrum activity against
Gram-positive bacteria by binding to the 70S initiation complex
of bacterial ribosomes and disrupting protein synthesis. In vitro
and animal studies have shown good activity against M. tubercu-
losis, and systematic reviews of off-label clinical use have shown
that its incorporation in MDR-TB and XDR-TB regimens improves
outcomes.51,52 It is orally administrable and considered one of
the most effective Group 5 anti-TB drugs.
As with other SLDs, evidence of anti-TB efficacy must be
balanced against side effects. In a patient cohort from South
Korea, 31/39 (87%) pulmonary XDR-TB patients who had not pre-
viously responded to chemotherapy achieved sputum culture
conversion within 6 months of adding linezolid to their OBR53;
27(69%) were still known to be sputum culture negative 1 year
later, and only four (10%) had confirmed linezolid failure.54
However, 82% had clinically significant adverse events, including
myelosuppression and peripheral or optic neuropathy within the
first 24 weeks. Similar results were observed during a clinical
trial in China.55 Some linezolid toxicity is dose-related and the
optimal dose in TB patients is uncertain. While 600 mg twice
daily is standard for non-TB bacterial infections, reduction to
300–600 mg once daily maybe adequate for TB.56 Detailed
pharmacology studies are required to establish whether dose
reduction to retain linezolid in multi-drug regimens for ≥6 months
(particularly in XDR-TB when alternatives are sparse) jeopardises
antibiotic exposure and promotes amplification of resistance.
In countries with high rates of HIV infection TB programme
providers may be particularly worried about linezolid safety,
because HIVdisease and ARTcan already cause bonemarrow tox-
icity and neuropathic complications, and less than 10% of existing
data on treatment outcomes using linezolid in MDR-TB come from
patients with HIV. A small amount of retrospective data from
MDR-TB and XDR-TB patients in South Africa and India suggests
that HIV infection increases the risk of linezolid side-effects,
but that improved treatment outcomes justify use of the drug.57
Outside the context of clinical trials (e.g., TB-Nix and PRACTECAL),
access to linezolid in low resource countries is restricted by price.
Non-proprietary drug sources may help to reduce costs, provided
quality can be assured.52
Newer oxazolidinones, including sutezolid and posizolid are
currently in Phase IIa clinical assessment. If these are effective,
with lower toxicity than linezolid, the oxazolidines may adopt
greater importance for MDR-TB treatment in the future.
Additional antibiotics and other options
Several additional antibiotics are listed as WHO Group 5 anti-TB
drugs. The fat-soluble rhiminophenzine dye, clofazimine, developed
in the 1950s, hasmainly been deployed to treat leprosy. Although it
does not demonstrate bactericidal therapy in the first 14 days of
treatment, there is some evidence that it improves longer term out-
comes58,59and the authors of the Bangladesh regimen have cited it
as an important component of their approach.24 There is less exten-
sive clinical evidence to support use of meropenem-clavulanic
acid,60 imipenem ormacrolides61 and the role of these drugs is nor-
mally limited to situations where extensive resistance, toxicity or
poor supply of medication rules out other options.
Supplementation of antibiotic therapy by treatments to aug-
ment host immunity have also been considered to enhance TB
therapy, andmay seem attractive for MDR-TB patients when anti-
biotic choices are restricted. However, trials of Vitamin D
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supplementation have not significantly improved outcomes62,63
and experimental host-directed therapies64 are unlikely to be
ready for clinical use in the foreseeable future. Surgery may be
an adjunct to chemotherapy, particularly for extensively resistant
but anatomically localised disease.65 Specialist centres are
required for this, which may not be easily accessible in low-
resource settings.
Facing the challenge
Ultimately, results of ongoing or planned clinical trials will indicate
whether short multi-drug combinations can be safely advocated
for MDR-TB treatment in low-resource settings, and whether
drugs from novel drug classes offer additional benefits. While
there are considerable grounds for optimism, important obstacles
confront all new therapeutic strategies.
Improved treatment must occur in tandem with better diag-
nostics for rapid, reliable diagnosis of MDR-TB. Improved molecu-
lar tests such as the forthcoming Xpert MTB/RIF Ultra assay66 and
refinements of line probe assays for detection of resistance to
SLDs will assist,67 but thesemust bemade comprehensively avail-
able for maximum impact.
Definitive data from MDR-TB trials will emerge slowly over
several years. In the meantime, healthcare providers must
work in the midst of uncertainty and evolving guidelines. The
European Respiratory Society/WHO have sought to develop an
International Consilium68 through which clinicians may present
and discuss complex cases. Such peer–peer consultation could
play an essential role in standardising and quality assuring the
use of new treatments.
Although novel agents such as delamanid and bedaquiline
were first assessed by single agent addition to an OBR, this trad-
itional approach to clinical trial design is inefficient for assessment
of a growing number of potential regimens. New tools, such as
multistage multiarm or adaptive trial designs, such as those pro-
posed for the PRACTECAL and endTB studies, may provide useful
information more quickly and should be considered for more
widespread use.
The issue of high costs of obtaining new TB drugs69 has been
noted throughout this review. In some settings, the expense can
be reduced by sourcing local non-proprietary drugs,70 and a high
financial outlay in obtaining effective therapy may be cost-
effective when downstream benefits of improved TB control are
also considered.71 However, drug procurement only represents
a proportion of the total cost of treating MDR-TB72; the entire
package of care includes a minimum of diagnostic tests, hospital-
isation, patient expenses and follow-up monitoring.73 Any weak-
nesses may result in treatment failure, amplification of resistance
and further setbacks for the global target of TB elimination.
Conclusions
In summary, the increased burden of MDR-TB represents a major
threat to TB control. New therapeutic strategies are gradually
emerging to reduce reliance on injectable agents, lessen toxicity
and shorten treatment duration. However, international co-
operation and sustained investment are required to establish
the most effective regimens, expand access to new drugs with-
out compromising safety, and integrate novel treatments into
co-ordinated TB control programmes alongside comprehensive
DST and robust mechanisms for patient support and monitoring.
Authors’ contributions: Both authors contributed to drafting and revising
the manuscript, and read and approved the final version. DS is the
guarantor of the paper.
Funding: This article received no specific funding. JL is supported by the
Wellcome Trust as a clinical PhD fellow [grant number 109105/Z/15/Z].
Competing interests: None declared.
Ethical approval: Not required.
References
1 WHO. MDG6: TB Target Acheived. Geneva: World Health Organization;
2015. http://www.who.int/tb/MDG_TBsuccess_factsheet.pdf [accessed
10 December 2015].
2 Uplekar M,Weil D, Lonnroth K et al. WHO’s new End TB Strategy. Lancet
2015;385:1799–801.
3 WHO. Global Tuberculosis Report 2014. Geneva: World Health
Organization; 2014.
4 WHO. Companion Handbook to the WHO Guidelines for the
Programmatic Management of Drug-Resistant Tuberculosis. Geneva:
World Health Organization; 2014.
5 Lange C, Abubakar I, Alffenaar J-WC et al. Management of patients
with multidrug-resistant/extensively drug-resistant tuberculosis in
Europe: a TBNET consensus statement. Eur Respir J 2014;44:23–63.
6 Pietersen E, Ignatius E, Streicher EM et al. Long-term outcomes of
patients with extensively drug-resistant tuberculosis in South Africa:
a cohort study. Lancet 2014;383:1230–9.
7 Malla P, Kanitz EE, Akhtar M et al. Ambulatory-based standardized
therapy for multi-drug resistant tuberculosis: Experience from Nepal,
2005–2006. PLoS One 2009;4:2005–6.
8 Sua´rez PG, Floyd K, Portocarrero J et al. Feasibility and cost-
effectiveness of standardised second-line drug treatment for chronic
tuberculosis patients: A national cohort study in Peru. Lancet
2002;359:1980–9.
9 Mirza IA, Khan FA, Khan KA et al. Extensively and pre-extensively drug
resistant tuberculosis in clinical isolates of multi-drug resistant
tuberculosis using classical second line drugs (levofloxacin and
amikacin). J Coll Physicians Surg Pak 2015;25:337–41.
10 Kurbatova E V, Dalton T, Ershova J et al. Additional drug resistance of
multidrug-resistant tuberculosis in patients in 9 countries. Emerg
Infect Dis 2015;21:977–83.
11 Bastos ML, Hussain H, Weyer K et al. Treatment outcomes of patients
with multidrug- and extensive drug-resistant tuberculosis according
to drug susceptibility testing to first- and second-line drugs:an
individual patient data meta-analysis. Clin Infect Dis 2014;59:
1364–74.
12 Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment
outcomes of multidrug-resistant tuberculosis: a systematic review
and meta-analysis. PLoS One 2009;4:e6914.
13 Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis:
implications in settings with weak healthcare systems. Int J Infect Dis
2015;32:118–23.
D. J. Sloan and J. M. Lewis
170
 at St A
ndrew
s U
niversity Library on A
pril 20, 2016
http://trstm
h.oxfordjournals.org/
D
ow
nloaded from
 
14 Cegielski JP, Dalton T, Yagui M et al. Extensive drug resistance acquired
during treatment of multidrug-resistant tuberculosis. Clin Infect Dis
2014;59:1049–63.
15 Falzon D, Jaramillo E, Schu¨nemann HJ et al. WHO guidelines for the
programmatic management of drug-resistant tuberculosis: 2011
update. Eur Respir J 2011;38:516–28.
16 Ahuja SD, Ashkin D, Avendano M et al. Multidrug resistant pulmonary
tuberculosis treatment regimens and patient outcomes:an individual
patient data meta-analysis of 9,153 patients. PLoS Med 2012;9:
e1001300.
17 Seddon JA, Godfrey-Faussett P, Jacobs K et al. Hearing loss in patients
on treatment for drug-resistant tuberculosis. Eur Respir J
2012;40:1277–86.
18 Kranzer K, Elamin WF, Cox H et al. A systematic review and
meta-analysis of the efficacy and safety of N-acetylcysteine in
preventing aminoglycoside-induced ototoxicity: implications for the
treatment of multidrug-resistant TB. Thorax 2015;70:1070–7.
19 Sturdy A, Goodman A, Jos´e RJ et al. Multidrug-resistant tuberculosis
(MDR-TB) treatment in the UK:A study of injectable use and toxicity
in practice. J Antimicrob Chemother 2011;66:1815–20.
20 Lytvynenko N, Cherenko S, Feschenko Y et al. Management of multi-
and extensively drug-resistant tuberculosis in Ukraine: how well are
we doing? Public Health Action 2014;4:S67–72.
21 Deshmukh RD, Dhande DJ, Sachdeva KS et al. Patient and provider
reported reasons for lost to follow up in MDRTB treatment: a
qualitative study from a drug resistant TB centre in India. PLoS One
2015;10:e0135802.
22 Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant
tuberculosis as a cause of death in patients co-infected with
tuberculosis and HIV in a rural area of South Africa. Lancet
2006;368:1575–80.
23 Brigden G, Nyang’wa B-T, du Cros P et al. Principles for designing future
regimens formultidrug-resistant tuberculosis. BullWorld Health Organ
2014;92:68–74.
24 Van Deun A, Maug AKJ, Salim MAH et al. Short, highly effective, and
inexpensive standardized treatment of multidrug-resistant
tuberculosis. Am J Respir Crit Care Med 2010;182:684–92.
25 Aung KJM, Van Deun A, Declercq E et al. Successful ‘9-month
Bangladesh regimen’ for multidrug-resistant tuberculosis among
over 500 consecutive patients. Int J Tuberc Lung Dis 2014;18:1180–7.
26 Kuaban C, Noeske J, Rieder HL et al. High effectiveness of a 12-month
regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis
2015;19:517–24.
27 Nuermberger E, Yew W-W. Expanding the evidence base supporting
shorter treatment durations for multidrug-resistant tuberculosis. Int
J Tuberc Lung Dis 2015;19:497–8.
28 Harausz E, Cox H, Rich M et al. QTc prolongation and treatment of
multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015;19:
385–91.
29 Nunn AJ, Rusen ID, Van Deun A et al. Evaluation of a standardized
treatment regimen of anti-tuberculosis drugs for patients with
multi-drug-resistant tuberculosis (STREAM):study protocol for a
randomized controlled trial. Trials 2014;15:353.
30 Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active
on the ATP synthase of Mycobacterium tuberculosis. Science
2005;307:223–7.
31 Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New
drugs and treatment regimens. Curr Respir Med Rev 2013;9:200–10.
32 Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for
multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397–405.
33 Diacon AH, Pym A, Grobusch MP et al. Multidrug-resistant tuberculosis
and culture conversion with bedaquiline. N Engl J Med 2014;371:
723–32.
34 Pym A, Diacon A, Conradie F et al. Bedaquiline as part of a multi-drug
resistant tuberculosis (MDR-TB) therapy regimen:final results of a
single-arm, phase II trial (C209). Int J Tuberc Lung Dis 2013;
17:(Suppl 2):S236.
35 Guglielmetti L, Le Duˆ D, Jachym M et al. Compassionate use of
bedaquiline for the treatment of multidrug-resistant and extensively
drug-resistant tuberculosis:interim analysis of a French cohort. Clin
Infect Dis 2015;60:188–94.
36 Ndjeka N, Conradie F, Schnippel K et al. Treatment of drug-resistant
tuberculosis with bedaquiline in a high HIV prevalence setting:an
interim cohort analysis. Int J Tuberc Lung Dis 2015;19:979–85.
37 WHO. The use of bedaquiline in the treatment of multidrug-resistant
tuberculosis: Interim policy guidance. Geneva: World Health
Organization; 2013.
38 Joint Formulary Commitee. British National Formulary. 69th ed.
London: BMJ Group and Pharmaceutical Press, 2015.
39 Stop TB Partnership. Stop TB Partnership’s Global Drug Facility to
distribute Bedaquiline (Sirturo) developed by Janssen. http://www.stoptb.
org/news/stories/2014/ns14_025.asp [accessed 10 December 2015].
40 Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a
nitro-dihydro-imidazooxazole derivative with promising action
against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466.
41 Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for
multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:
2151–60.
42 Skripconoka V, Danilovits M, Pehme L et al. Delamanid improves
outcomes and reduces mortality in multidrug-resistant tuberculosis.
Eur Respir J 2013;41:1393–400.
43 Gupta R, Geiter LJ, Wells CD et al. Delamanid for extensively
drug-resistant tuberculosis. N Engl J Med 2015;373:291–2.
44 WHO. The use of Delamanid in the Treatment of Multidrug-Resistant
Tuberculosis: Interim Policy Guidance. Geneva: World Health
Organization; 2014.
45 Davies GR, Phillips PPJ, Jaki T. Adaptive clinical trials in tuberculosis:
applications, challenges and solutions. Int J Tuberc Lung Dis
2015;19:626–34.
46 European Medicines Agency. Deltyba: Summary of Product
Characteristics. London: European Medicines Agency; 2014.
47 Gruber K. Access sought to tuberculosis drug from nutraceutical
company. Nat Med 2015;21:103.
48 Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day
bactericidal activity of PA-824, bedaquiline, pyrazinamide, and
moxifloxacin combinations:a randomised trial. Lancet 2012;380:
986–93.
49 Dawson R, Diacon AH, Everitt D et al. Efficiency and safety of
the combination of moxifloxacin, pretomanid (PA-824), and pyrazina-
mide during the first 8 weeks of antituberculosis treatment:a phase
2b, open-label, partly randomised trial in patients with drug-
susceptible or drug-resistant pulmonary tuberculosis. Lancet
2015;385:1738–47.
50 Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. Bactericidal
activity of pyrazinamide and clofazimine alone and in combinations
with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015;
191:943–53.
51 Cox H, Ford N. Linezolid for the treatment of complicated
drug-resistant tuberculosis:a systematic review and meta-analysis.
Int J Tuberc Lung Dis 2012;16:447–54.
Transactions of the Royal Society of Tropical Medicine and Hygiene
171
 at St A
ndrew
s U
niversity Library on A
pril 20, 2016
http://trstm
h.oxfordjournals.org/
D
ow
nloaded from
 
52 Sotgiu G, Centis R, D’Ambrosio L et al. Efficacy, safety and tolerability of
linezolid containing regimens in treating MDR-TB and XDR-TB:
systematic review and meta-analysis. Eur Respir J 2012;40:1430–42.
53 Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic
extensively drug-resistant tuberculosis. N Engl J Med 2012;367:
1508–18.
54 Lee M, Cho SN, Barry CE et al. Linezolid for XDR-TB–final study
outcomes. N Engl J Med 2015;373:290–1.
55 Tang S, Yao L, Hao X et al. Efficacy, safety and tolerability of linezolid for
the treatment of XDR-TB:a study in China. Eur Respir J 2015;
45:161–70.
56 Koh W-J, Kang YR, Jeon K et al. Daily 300 mg dose of linezolid for
multidrug-resistant and extensively drug-resistant tuberculosis:
updated analysis of 51 patients. J Antimicrob Chemother 2012;
67:1503–7.
57 Bolhuis MS, Tiberi S, Sotgiu G et al. Linezolid tolerability in multidrug-
resistant tuberculosis:a retrospective study. Eur Respir J 2015;46:
1205–7.
58 Gopal M, Padayatchi N, Metcalfe JZ, O’Donnell MR. Systematic reviewof
clofazimine for the treatment of drug-resistant tuberculosis. Int J
Tuberc Lung Dis 2013;17:1001–7.
59 Padayatchi N, Gopal M, Naidoo R et al. Clofazimine in the treatment of
extensively drug-resistant tuberculosis with HIV coinfection in South
Africa: a retrospective cohort study. J Antimicrob Chemother
2014;69:3103–7.
60 Davies Forsman L, Giske CG, Bruchfeld J et al. Meropenem-clavulanic
acid has high in vitro activity against multidrug-resistant Mycobacterium
tuberculosis. Antimicrob Agents Chemother 2015;59:3630–2.
61 van der Paardt A-F, Wilffert B, Akkerman OW et al. Evaluation of
macrolides for possible use against multidrug-resistant Mycobacterium
tuberculosis. Eur Respir J 2015;46:444–55.
62 Martineau AR, Timms PM, Bothamley GH et al. High-dose vitamin D(3)
during intensive-phase antimicrobial treatment of pulmonary
tuberculosis: a double-blind randomised controlled trial. Lancet
2011;377:242–50.
63 Tukvadze N, Sanikidze E, Kipiani M et al. High-dose vitamin D3 in adults
with pulmonary tuberculosis: a double-blind randomized controlled
trial. Am J Clin Nutr 2015;102:1059–69.
64 Zumla A, Maeurer M. Host-directed therapies for tackling multi-drug
resistant tuberculosis:learning from the Pasteur-Bechamp debates.
Clin Infect Dis 2015;61:1432–8.
65 Francis RS, Curwen MP. Major surgery for pulmonary tuberculosis. Final
report. Tubercle 1964;45(Suppl):5–79.
66 Alland D, Rowneki M, Smith L et al. Xpert MTB/RIF Ultra: A New
Near-Patient TB Test With Sensitivity Equal to Culture. Conf
Retroviruses Opportunistic Infect 2015 Abstr 91. http://www.
croiconference.org/sessions/xpert-mtbrif-ultra-new-near-patient-
tb-test-sensitivity-equal-culture [accessed 10 December 2015].
67 Molina-Moya B, Lacoma A, Prat C et al. AID TB resistance line probe
assay for rapid detection of resistant Mycobacterium tuberculosis in
clinical samples. J Infect 2015;70:400–8.
68 D’Ambrosio L, Tadolini M, Centis R et al. Supporting clinical
management of the difficult-to-treat TB cases: the ERS-WHO TB
Consilium. Int J Infect Dis 2015;32:156–60.
69 Lunte K, Cordier-Lassalle T, Keravec J. Reducing the price of treatment
for multidrug-resistant tuberculosis through the Global Drug Facility.
Bull World Health Organ 2015;93:279–82.
70 Qadeer E, Fatima R, Fielding K et al. Good quality locally procured drugs
can be as effective as internationally quality assured drugs in treating
multi-drug resistant tuberculosis. PLoS One 2015;10:e0126099.
71 Wolfson LJ, Walker A, Hettle R et al. Cost-effectiveness of adding
bedaquiline to drug regimens for the treatment of multidrug-
resistant tuberculosis in the UK. PLoS One 2015;10:e0120763.
72 Cox H, Ramma L, Wilkinson L et al. Cost per patient of treatment for
rifampicin-resistant tuberculosis in a community-based programme
in Khayelitsha, South Africa. Trop Med Int Health 2015;20:1337–45.
73 Li R, Ruan Y, Sun Q et al. Effect of a comprehensive programme to
provide universal access to care for sputum-smear-positive
multidrug-resistant tuberculosis in China: a before-and-after study.
Lancet Glob Health 2015;3:e217–28.
D. J. Sloan and J. M. Lewis
172
 at St A
ndrew
s U
niversity Library on A
pril 20, 2016
http://trstm
h.oxfordjournals.org/
D
ow
nloaded from
 
